A Breath of Fresh Air: The Fight for Affordable Asthma Inhalers

"On January 17, 2024, the U.S. Court of Appeals for the Federal Circuit affirmed a lower district court order against pharmaceutical maker Teva requiring the drugmaker to delist several asthma inhaler patents from the Food and Drug Administration’s (FDA) Orange Book. The appellate court order stems from a case brought by Teva against drugmaker Amneal, with the FTC previously urging delisting of Teva's patents due to their improper listing in the FDA's Orange Book."